Cancer
Dual targeting
NRP-1
Nanobody
Single domain antibody
VEGF
Journal
Iranian journal of basic medical sciences
ISSN: 2008-3866
Titre abrégé: Iran J Basic Med Sci
Pays: Iran
ID NLM: 101517966
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
6
11
2020
Statut:
ppublish
Résumé
Emergence of resistant tumor cells to the current therapeutics is the main hindrance in cancer treatment. Combination therapy, which mixes two or more drugs, is a way to overcome resistant problems of cancer cells to current treatments. Nanobodies are promising tools in cancer therapy due to their high affinity as well as high penetration to tumor sites. Here, the inhibitory effect of mixtures of two nanobodies (anti-vascular endothelial growth factor (VEGF) and anti-neuropilin-1 (NRP-1) nanobodies) on tube formation of human endothelial cells Results showed that combination of two drugs significantly inhibited proliferation and tube formation of human endothelial cells. In addition, mixtures of two nanobodies inhibited angiogenesis in chick chorioallantoic membrane (CAM) assay efficiently compared with each individual nanobody. Results highlight the efficacy of combination therapy of cancer compared with mono-therapy and promises development of novel anti-cancer therapeutics based on nanobodies targeting two or more targets of tumor cells.
Identifiants
pubmed: 33149867
doi: 10.22038/ijbms.2020.47782.11000
pmc: PMC7585540
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1335-1339Références
Mol Cancer Res. 2010 Aug;8(8):1063-73
pubmed: 20651020
Cell. 2010 Jan 22;140(2):268-79
pubmed: 20141840
Cancer Cell. 2007 Jan;11(1):53-67
pubmed: 17222790
Acta Ophthalmol. 2011 Feb;89(1):76-81
pubmed: 21272288
J Adv Res. 2017 Nov;8(6):591-605
pubmed: 28808589
Biochem Soc Trans. 2014 Dec;42(6):1623-8
pubmed: 25399580
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Target Oncol. 2016 Aug;11(4):501-5
pubmed: 26916409
Elife. 2014 Sep 22;3:e03720
pubmed: 25244320
Iran J Basic Med Sci. 2018 Mar;21(3):260-266
pubmed: 29511492
J Exp Med. 2012 Mar 12;209(3):507-20
pubmed: 22393126
J Biol Chem. 2000 Sep 1;275(35):26690-5
pubmed: 10842181
Cell Mol Life Sci. 2006 Mar;63(5):601-15
pubmed: 16465447
Nature. 2005 Dec 15;438(7070):967-74
pubmed: 16355214
FEBS Lett. 2006 May 22;580(12):2879-87
pubmed: 16631753
Cell. 1998 Mar 20;92(6):735-45
pubmed: 9529250
Ophthalmology. 2011 Mar;118(3):523-30
pubmed: 20920825
Biochem J. 2008 Apr 15;411(2):211-26
pubmed: 18363553
J Biochem. 2013 Jan;153(1):13-9
pubmed: 23172303
Oncol Res Treat. 2018;41(4):166-171
pubmed: 29562226
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3071-6
pubmed: 10077638
Mol Immunol. 2015 May;65(1):58-67
pubmed: 25645505
Cardiovasc Res. 2001 Feb 16;49(3):568-81
pubmed: 11166270
J Exp Med. 2014 Jun 2;211(6):1167-83
pubmed: 24863063
J Biol Chem. 1997 Dec 12;272(50):31582-8
pubmed: 9395496
Cancer Res. 2001 Aug 1;61(15):5736-40
pubmed: 11479209
Oncotarget. 2012 Sep;3(9):921-39
pubmed: 22948112
Nat Med. 2003 Jun;9(6):669-76
pubmed: 12778165
Br J Cancer. 2005 Jan 31;92(2):328-33
pubmed: 15655556
Cancer Gene Ther. 2017 Jan;24(1):33-37
pubmed: 27982020